GET DAILY SIGNALSGenmab (GMAB) Advances +47% in 30 Days on Strong Oncology Readouts
Key Takeaways
- GMAB rose roughly 47% over the trailing 30 days, moving from about $36.57 to $53.87 per share at the latest close.
- The advance was driven by three positive late-stage oncology results involving Rina-S, Epkinly, and petosemtamab.
- Petosemtamab's Phase 3 LiGeR-HN1 trial met both co-primary endpoints, demonstrating a 50% reduction in the risk of death versus Keytruda alone in head and neck cancer.
- Rina-S cut the risk of disease progression or death by 71% versus chemotherapy in platinum-resistant ovarian cancer.
- The results prompted analyst upgrades, including JPMorgan moving to Overweight with a higher price target.
- Over the trailing quarter, GMAB gained roughly 71%, pointing to a broader re-rating of its pipeline.
Genmab's Place in Biotech
Genmab A/S is a Danish biotechnology firm specializing in antibody-based treatments for cancer and other serious conditions. It relies on platforms like DuoBody and HexaBody to develop bispecific and enhanced antibodies. Its flagship product, daratumumab (Darzalex), is sold by JNJ in multiple myeloma and provides significant royalty revenue. Royalties also flow from ofatumumab (Kesimpta), marketed by NVS.
The company is shifting toward wholly owned assets such as epcoritamab (Epkinly), developed with ABBV, along with petosemtamab and Rina-S. Pipeline updates can materially affect long-term revenue views beyond royalty streams, which is why I follow GMAB closely.
GMAB Stock Performance Over 30 Days and the Quarter
In the trailing 30 days, GMAB moved from a close near $36.57 to $53.87, for a gain of about 47%. Shares surged sharply on October 28 after the petosemtamab readout and briefly reached an intraday high around $59.97. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The quarterly picture is stronger still. From a mid-August close near $31.42, the stock climbed roughly 71%. Successive clinical and regulatory milestones have supported a sustained re-rating, with investors viewing Genmab more as a multi-asset oncology player than a royalty-focused biotech.
Drivers of the 30-Day Move
A string of positive late-stage data served as the main catalyst. Rina-S, a wholly owned antibody-drug conjugate, succeeded in the Phase 3 RAINFOL-02 trial in platinum-resistant ovarian cancer, lowering the risk of progression or death by 71% versus chemotherapy. Epkinly showed positive Phase 3 results in diffuse large B-cell lymphoma, reducing the risk of progression or death by 51% in newly diagnosed patients.
The standout event occurred on October 28, when petosemtamab plus Merck's (MRK) Keytruda met both co-primary endpoints in the Phase 3 LiGeR-HN1 trial for first-line head and neck squamous cell carcinoma, cutting the risk of death by 50% versus Keytruda alone. Full rights to petosemtamab make this readout especially relevant for future revenue. From what I see, these outcomes led to upgrades, including JPMorgan shifting to Overweight with a higher target, while Jefferies and Van Lanschot Kempen also raised estimates. The stock added more than $10 billion in market value in one week. Genmab also announced a collaboration with Incyte (INCY) to test petosemtamab with a KRAS G12D inhibitor.
Quarterly Momentum and the Bigger Picture
The quarterly gain reflects a shift in narrative. For years, value centered on Darzalex royalties from JNJ, with questions around sustainability. The recent Phase 3 successes in ovarian cancer, lymphoma, and head and neck cancer show a broader pipeline that can support independent commercialization.
This reduced concentration concerns and prompted institutional re-rating toward a growth-oriented model. Earlier positive Phase 3 data for epcoritamab in diffuse large B-cell lymphoma with ABBV added to the momentum, while rising price targets and estimates reflected greater confidence in commercial potential.
Key Factors to Monitor Going Forward
Upcoming earnings and guidance on Darzalex royalties and expenses will be important. Detailed data at medical meetings could support or temper the recent re-rating for petosemtamab, Rina-S, and Epkinly. Regulatory steps for these assets are also worth watching. Additional elements include the Incyte (INCY) combination studies, competitive oncology programs, and JNJ Darzalex sales trends. Broader market conditions and biotech sentiment may influence price action after the sharp move higher.
Exploring AI Tools in My Research Process
I frequently review Tickeron’s AI Trading Bots to observe how automated strategies are handling names like GMAB during periods of momentum. The platform aggregates top-performing bots from a large marketplace, covering different timeframes and approaches such as momentum or pattern recognition. This helps me cross-check human analysis with systematic signals without replacing my own judgment. Trending AI Robots provides a useful starting point for reviewing available strategies and their recent performance metrics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Momentum Indicator for GMAB turns negative, indicating new downward trend
GMAB saw its Momentum Indicator move below the 0 level on November 11, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 82 similar instances where the indicator turned negative. In 58 of the 82 cases, the stock moved further down in the following days. The odds of a decline are at 71%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for GMAB moved out of overbought territory on November 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 41 similar instances where the indicator moved out of overbought territory. In 25 of the 41 cases, the stock moved lower in the following days. This puts the odds of a move lower at 61%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 39 of 58 cases where GMAB's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GMAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
GMAB broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Moving Average Convergence Divergence (MACD) for GMAB just turned positive on October 19, 2026. Looking at past instances where GMAB's MACD turned positive, the stock continued to rise in 30 of 43 cases over the following month. The odds of a continued upward trend are 70%.
Following a +5.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where GMAB advanced for three days, in 200 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
The Aroon Indicator entered an Uptrend today. In 152 of 213 cases where GMAB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 3 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. GMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 75 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.536) is normal, around the industry mean (3.498). P/E Ratio (41.866) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (4.454) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.192) is also within normal values, averaging (440.869).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an international biotechnology company, which develops human antibody therapeutics for the treatment of cancer and other diseases.
Industry Biotechnology
Advertisement